News

Investigators have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease.

Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.

Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines.

A share of a £100 million Government cash injection is awarded to accelerate growth and jobs in Enterprise Zones across the UK.

Company announces financial results for the fourth quarter and fiscal year 2013.

The acquisition consideration of approximately $207.5 million consists of a combination of Fluidigm common stock and cash.

The universe of cancer mutations is much bigger than previously thought, and key cancer genes are still to be discovered.

UCB announces the global launch of its ‘Innovation Challenge’ which seeks to find rare phenotypes.

Rice University team quantifies how mutations affect cell signaling in bacteria.

Sony and M3 establish a new company with Illumina as a minority investor to launch a "genome information platform" in Japan.